Want to see AU:OSX full AI Analyst Report?
Top Page
Osteopore Ltd.
(Sydney:OSX)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by weak financial performance: ongoing losses, continued cash burn, and negative equity outweigh strong revenue growth and reduced debt. Technical and valuation inputs are largely unavailable or not meaningful (missing indicators; negative P/E and no dividend yield), contributing a neutral-to-slightly negative impact.
Positive Factors
Sustained Revenue Growth
Multi-year revenue expansion demonstrates durable commercial traction for Osteopore’s bioresorbable implants, signaling growing adoption by hospitals and distributors. Persistent top-line growth supports scale benefits, broader market penetration and a foundation for future operating leverage as fixed costs are absorbed.
Negative Factors
Persistent Net Losses
Continued multi‑million net losses reflect an ongoing inability to cover operating costs from revenue. This structural loss profile requires external financing or dilution, constrains reinvestment into sales and R&D, and delays a durable path to profitability absent material margin or cost improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Multi-year revenue expansion demonstrates durable commercial traction for Osteopore’s bioresorbable implants, signaling growing adoption by hospitals and distributors. Persistent top-line growth supports scale benefits, broader market penetration and a foundation for future operating leverage as fixed costs are absorbed.
Read all positive factors
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.77M
Dividend YieldN/A
Average Volume (3M)2.16M
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth10.65%
EPS Growth31.72%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.02
Shares Outstanding693,592,900
10 Day Avg. Volume675,672
30 Day Avg. Volume2,156,422
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.70
Price to Sales (P/S)0.40
P/FCF Ratio-0.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Osteopore Ltd. Business Overview & Revenue Model
Company Description
Established in Singapore in 2003, Osteopore Limited focuses on engineering, manufacturing, and globally commercializing bioresorbable polymer implants. These advanced devices are utilized in neurosurgical, orthopedic, and maxillofacial operations ...
How the Company Makes Money
Osteopore primarily makes money by selling its bioresorbable scaffold implants and related surgical products for use in patient procedures. Revenue is generated when hospitals/clinics (or their procurement groups) purchase Osteopore’s implants eit...
Osteopore Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.06M | 2.81M | 2.22M | 1.69M | 1.11M |
| Gross Profit | 1.62M | 2.37M | 1.64M | 1.27M | 811.64K |
| EBITDA | -1.92M | -2.34M | -4.35M | -3.97M | -3.38M |
| Net Income | -3.72M | -3.35M | -4.87M | -4.22M | -3.62M |
Balance Sheet | |||||
| Total Assets | 2.77M | 3.13M | 3.34M | 3.62M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 626.97K | 638.50K | 1.16M | 1.35M | 4.55M |
| Total Debt | 198.80K | 1.33M | 1.09M | 74.18K | 106.71K |
| Total Liabilities | 4.50M | 2.83M | 2.91M | 1.51M | 633.40K |
| Stockholders Equity | -1.73M | 306.22K | 432.60K | 2.11M | 5.37M |
Cash Flow | |||||
| Free Cash Flow | -2.57M | -3.10M | -3.74M | -4.06M | -4.00M |
| Operating Cash Flow | -2.56M | -3.09M | -3.74M | -4.00M | -3.81M |
| Investing Cash Flow | -10.79K | -14.59K | -7.37K | -63.98K | -194.62K |
| Financing Cash Flow | 2.67M | 2.63M | 3.58M | 896.32K | -485.88K |
Osteopore Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$207.54M | 31.87 | 7.55% | ― | 19.23% | ― | |
61 Neutral | AU$666.66M | 72.03 | 11.87% | ― | 19.36% | 66.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$5.14M | -1.29 | -29.91% | ― | 82.28% | 13.33% | |
46 Neutral | AU$10.60M | -2.25 | -161.62% | ― | 76.94% | 42.95% | |
42 Neutral | AU$2.77M | -0.20 | 346.27% | ― | 10.65% | 31.72% | |
41 Neutral | AU$209.70M | -15.03 | -44.80% | ― | 49.03% | -232.68% |
* Healthcare Sector Average
AU:OSX
Osteopore Ltd.
0.01
0.00
0.00%
AU:PNV
Polynovo
1.01
-0.20
-16.18%
AU:OCC
Orthocell Ltd
0.77
-0.51
-39.76%
AU:TRP
Tissue Repair Ltd
0.08
-0.22
-73.33%
AU:CMB
Regeneus Ltd.
0.40
0.03
8.11%
AU:ARX
Aroa Biosurgery Ltd
0.58
-0.06
-9.38%
Osteopore Ltd. Corporate Events
Osteopore switches auditors to Pitcher Partners to bolster governance
Aug 3, 2026
Osteopore Limited has appointed Pitcher Partners BAA Pty Ltd as its new external auditor, effective 31 July 2026, following the resignation of Grant Thornton Audit Pty Ltd and approval of the change by ASIC under the Corporations Act. The board se...
Osteopore Misses Q2 Targets but Gains Asian Orthopaedic Approvals
Jul 30, 2026
Osteopore reported quarterly revenue of AUD 676,000 for the three months to 30 June 2026, with performance slightly below expectations due to slower-than-anticipated uptake of its custom-made cranioplasty products and ongoing distribution transiti...
Osteopore Seeks ASX Quotation for 15.2 Million New Shares
Jul 23, 2026
Osteopore Ltd has applied to the ASX for quotation of 15,151,515 new ordinary fully paid shares under its existing OSX ticker, with an issue date of 23 July 2026. The additional share quotation expands the company’s listed equity base, which...
Osteopore Gains Saudi Arabia Market Access for Craniofacial Implants
Jul 6, 2026
Osteopore has secured market access to Saudi Arabia for its craniofacial implants via its distribution partnership with Zimmer Biomet, expanding on earlier launches in Europe, Australia and Hong Kong that have already driven a three-fold increase ...
Osteopore Treats First Patient in Jaw Reconstruction Implant Trial
Jun 30, 2026
Osteopore has reported the successful treatment of the first patient in a jaw reconstruction clinical trial at Brisbane’s Princess Alexandra Hospital, using its novel 3D-printed bioresorbable implant tailored to the patient’s anatomy. ...
Osteopore advances paediatric cleft lip trial with first implants at Queensland Children’s Hospital
Jun 28, 2026
Osteopore Limited has reported that the first two paediatric patients in its cleft lip augmentation clinical trial at Queensland Children’s Hospital have successfully received their 3D-printed bioresorbable implants. The single-arm feasibili...
Osteopore Completes Patient Recruitment for Cleft Lip Implant Trial at Queensland Children’s Hospital
Jun 25, 2026
Osteopore has completed recruitment of all five paediatric patients for a Queensland Children’s Hospital clinical trial evaluating its 3D-printed bioresorbable scaffolds for paranasal augmentation in children with unilateral cleft lip. The s...
Osteopore Wins Neurosurgery Product Approval at Major Thai Medical Centre
Jun 23, 2026
Osteopore Ltd has secured approval for its neurosurgery products at Thammasat University Hospital, a major teaching and tertiary care centre in Bangkok serving thousands of outpatients daily and operating more than 800 inpatient beds. The move fol...
Osteopore Issues Additional Unquoted Convertible Notes
Jun 22, 2026
Osteopore Ltd has notified the market of the issuance of additional unquoted convertible notes, with five securities recorded under its OSXAM convertible notes line. The notes were issued on June 22, 2026, and the filing formalises this capital-re...
Osteopore Extends Tranche 2 Drawdown in A$20m Note Program
Jun 22, 2026
Osteopore Limited has continued to draw on its previously arranged funding facility, confirming that subscribers have taken up an additional sub-tranche of Tranche 2 redeemable convertible notes worth A$250,000. This latest drawdown lifts the comp...
Osteopore Marks First Custom Orthopaedic Reconstruction in Hong Kong
Jun 21, 2026
Osteopore has completed its first custom orthopaedic reconstruction case in Hong Kong, using a 3D-printed bioresorbable implant to correct a wrist deformity at Queen Mary Hospital under Clinical Associate Professor Christian Fang. The custom impla...
Osteopore Ships First Dental Order Under DKSH Deal to Tap Malaysia’s Growing Regeneration Market
Jun 16, 2026
Osteopore has delivered its first batch of dental products in Malaysia under a five-year distribution partnership with DKSH, marking the start of commercial activities for its dental portfolio in the country. The off-the-shelf products, used in Gu...
Advance Opportunities Fund I exits substantial holding in Osteopore
Jun 9, 2026
Osteopore Limited has disclosed that Advance Opportunities Fund I has ceased to be a substantial shareholder in the company, following a series of on-market share sales. According to the notice filed under the Corporations Act, the fund gradually ...
Osteopore Seeks ASX Quotation for Over 52 Million New Shares
Jun 8, 2026
Osteopore Limited has applied for quotation on the ASX of 52,083,333 new ordinary fully paid shares, which were issued on 5 June 2026. The additional securities expand the company’s quoted share capital and may provide greater liquidity and ...
Osteopore Backs New Cleft Lip Trial With 3D-Printed Implants at QCH
Jun 1, 2026
Osteopore Ltd and Queensland Children’s Hospital have launched a single-arm feasibility clinical trial using Osteopore’s 3D-printed, bioresorbable mPCL-TCP scaffolds for paranasal augmentation in up to five paediatric patients with uni...
Osteopore Wins Hainan Approval, Opening Fast-Track Route Into China Orthopaedics Market
May 26, 2026
Osteopore Ltd has secured approval from the Hainan Medical Products Administration for the clinical use and sale of its custom orthopaedic medical devices at the Hainan branch of Shanghai Ruijin Hospital, within China’s Boao Lecheng Internat...
Osteopore Wins Strong Shareholder Backing at AGM, Secures 10% Placement Facility
May 21, 2026
Osteopore Limited reported that all resolutions put to shareholders at its Annual General Meeting on 21 May 2026 were passed on a poll, including a special resolution approving a 10% placement facility. Investors strongly backed the remuneration r...
Osteopore Issues Cleansing Notice for New Securities
May 12, 2026
Osteopore Limited has issued a cleansing notice to the ASX in relation to newly issued securities, confirming they were offered without a prospectus under the Corporations Act disclosure exemptions. The company states it is in compliance with its ...
Osteopore Seeks ASX Quotation for 11.75 Million New Shares
May 12, 2026
Osteopore Limited has applied for quotation on the ASX of 11,750,000 fully paid ordinary shares, expanding the number of its listed securities. The new shares, some of which were issued under an employee incentive scheme, are dated 11 May 2026 and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.